Yang 2001.

Methods	Randomised controlled trial undertaken in China.
Participants	400 primiparous women with term singleton pregnancy, vertex presentation, spontaneous delivery, normal antenatal care, no antepartum haemorrhage, no above moderate PIH, no polyhydramnios, no abnormal birth process or other complications were enrolled in the 2nd stage of labour. Had 10 units of oxytocin injected immediately post delivery.
Interventions	4 groups: I) ‐ TA 1 g IV (N = 94), 2) ‐ TA 0.5 g IV (N = 92), 3) ‐ aminomethylbenzoic acid 0.5 g IV (N = 92), 4) ‐ no treatment (N = 87). TA was given IV 2 to 3 minutes after the delivery.
Outcomes	Incidence of PPH, mean blood loss (from placental delivery until 2 hours postpartum), side effects.
Notes	Aminomethylbenzoic acid is an antifibrinolytic. There was no placebo used in group 4. Not blinded.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly assigned to 4 groups.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Open labelled.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	High risk	35 cases of fetal macrosomia (> 4000 g) were excluded from the study.
Selective reporting (reporting bias)	Unclear risk	No prior publication/registration of protocol.
Other bias	Unclear risk	We have combined 2 groups which received 2 different doses of TA using the above‐described methods. We did not include a group that received aminomethylbenzoic acid in this analysis.